24 febrero 2015
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
http://feeds.sciencedaily.com/~r/sciencedaily/~3/4_qAYxQCAfc/150224091713.htm
